Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Non-Current Liabilities (2022 - 2025)

Axsome Therapeutics' Total Non-Current Liabilities history spans 4 years, with the latest figure at $524.0 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 24.81% year-over-year to $524.0 million; the TTM value through Dec 2025 reached $524.0 million, up 24.81%, while the annual FY2025 figure was $524.0 million, 24.81% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $524.0 million at Axsome Therapeutics, up from $505.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $524.0 million in Q4 2025 and bottomed at $136.0 million in Q2 2022.
  • The 4-year median for Total Non-Current Liabilities is $331.7 million (2024), against an average of $342.3 million.
  • The largest annual shift saw Total Non-Current Liabilities soared 120.05% in 2023 before it increased 24.81% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $190.8 million in 2022, then skyrocketed by 69.77% to $324.0 million in 2023, then rose by 29.59% to $419.8 million in 2024, then rose by 24.81% to $524.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Total Non-Current Liabilities are $524.0 million (Q4 2025), $505.7 million (Q3 2025), and $487.1 million (Q2 2025).